This is a clinical trial to assess the safety, tolerability and pharmacokinetics (i.e. what the body does to a drug) of an experimental drug (MT-3921) in persons with spinal cord injury. If included, the participant will receive a single low dose of the MT-3921 drug injected into a vein. If the drug seems to be well tolerated, the participant will receive a high dose of the MT-3921 drug. Blood samples will be collected at 0, 1, 4, 8 hours, 1, 2, 7 days, and 1, 2, 3, 6 months after receiving the drug. This drug is an antibody treatment that has been shown in animal studies (e.g. mice and monkeys) to act against molecules that prevent guidance of regenerating nerve fibres.
Traumatic
Non-traumatic
Type
Details
The participant will receive a single low dose of the MT-3921 drug injected into a vein. If the drug seems to be well tolerated, the participant will receive a high dose of the MT-3921 drug. Blood samples will be collected at 0, 1, 4, 8 hours, 1, 2, 7 days, and 1, 2, 3, 6 months after receiving the drug.
Main benefits
General health
Additional benefits
Good to know: Potential benefits are defined as outcomes that are being measured during and/or after the trial.
Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.
Learn moreWings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.
Learn more